AAP
ITOS

Arax Advisory Partners’s iTeos Therapeutics ITOS Stock Holding History

Arax Advisory Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-95
Closed -$970 – 2578
2024
Q3 		$970 Hold
95
– – ﹤0.01% 2268
2024
Q2 		$1.41K Buy
+95
New +$1.36K ﹤0.01% 2076

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Arax Advisory Partners's ITOS Position: Q4 2024 in Review

Arax Advisory Partners sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 95 shares — an estimated $970 sold.

Arax Advisory Partners first reported a position in ITOS in Q2 2024 and held it in 2 quarters. The position peaked at $1.41K in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Arax Advisory Partners reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 95 iTeos Therapeutics shares in Q4 2024, an estimated $970.
  • Arax Advisory Partners first reported a position in iTeos Therapeutics in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's iTeos Therapeutics position peaked at $1.41K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.